Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.
Press releases published on June 18, 2025
Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
GlobeNewswire
·
June 18, 2025
NEW YORK and PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership …
TOLREMO therapeutics Announces Strengthening of Leadership: Alessandra Cesano Joins Board of Directors, Florian D. Vogl Appointed Chief Medical Officer
GlobeNewswire
·
June 18, 2025
Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of solid tumors and multiple myeloma, today announced key …
Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UK
GlobeNewswire
·
June 18, 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a strategic partnership with Standard Health www.standardhealth.co.uk to support the development of the first-ever Orthopaedic Ambulatory Surgery Centre in the UK. …
Bavarian Nordic sælger Priority Review Voucher for USD 160 mio.
GlobeNewswire
·
June 18, 2025
KØBENHAVN, Danmark, 18. juni 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået aftale om salg af sin Priority Review Voucher (PRV) for USD 160 mio. kontant. Bavarian Nordic blev tildelt voucheren i februar 2025 i forbindelse …
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
GlobeNewswire
·
June 18, 2025
COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in …
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
GlobeNewswire
·
June 18, 2025
Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will …
Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
GlobeNewswire
·
June 18, 2025
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of novel, potentially transformative treatments Proceeds will fund four clinical studies: two related to the …
Biomea Fusion Announces Pricing of Public Offering of Securities
GlobeNewswire
·
June 18, 2025
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19, …
Participation in “The 113th Congress of Japan Society of Aesthetic Surgery,” May 2025
GlobeNewswire
·
June 18, 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”) today announced that a total of 22 representatives, including Yoshiyuki Aikawa, CEO of SBC Medical, and doctors from Shonan Beauty …
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42
GlobeNewswire
·
June 18, 2025
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round. Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its …